| November 21, 2013 | ISSUE NUMBER 325 VOL 11 |
Digital Pharma
Has Pharma Finally Figured Out Social Media?
For years, tightly regulated pharma companies have been tip-toeing across the social media landscape as if it was a minefield. Given the implications of getting it wrong, that’s not surprising. A radical shift towards partnering with patients means that things are finally changing. But how does pharma now take advantage of social media? ...Read more
Digital Pharma
Can Big Pharma Solve Its Fixed Cost Problem by Going Virtual?
Not entirely, writes Ben Comer, but drug companies can get more out of their CRO partners by treating them less like avatars and more like equals ...Read more
Special Report
Typhoon Trauma: The Pharma Score on Disaster Relief
Big Pharma quietly stepped up to provide critical supplies of essential medicines, other health equipment, and skilled local personnel to areas of the Philippines devastated by Typhoon Haiyan this month ...Read more
Scivigilance – Pharmacovigilance in a box
Technology and process enhancements play a crucial role in effective management of pharmacovigilance. Technology fosters collaboration between disparate teams, enables seamless flow of data, intuitive collection, processing and analysis of data. Cumulatively, effective combination of domain expertise, agile process and robust technology has allowed us to consistently demonstrate time savings, high quality, cost reductions, increased efficiency and absolute compliance.
The  whitepaper examines the use of scientific expertise, LEAN process and technology to deliver enhanced efficiency and compliance.
Global
Doubts Over Data Disclosure in Europe
The European Medicines Agency has admitted that it can’t meet its deadline on the disclosure of clinical trial data. Has it bitten off more than it can chew? Reflector reports ...Read more
Pharmaceutical Executive editorial staff proudly introduces PharmExec TV, their latest high quality pertinent content in a brand new industry-breaking format. Tune In Now
Global
What Does the UK’s ‘New’ PPRS Mean for Value-Based Medicine?
Leela Barham ponders the future of value-based medicine in the UK in light of a new PPRS deal between industry and the UK government ...Read more
New E-Book- Lifecycle Solutions: Positioning Pharmaceuticals For Commercial Success
Time is risk. If time to market is slowed then the cost for a company is lost revenues, profits, and ultimately lost opportunities for patients. The message is clear. To compete and win, companies must wrest more value from every stage of a new product’s tightly projected lifecycle. Download Now
Video
Paving the Way for Therapeutic Vaccines
The PhRMA awards bring together stakeholders to foster vaccine development system ...View here
|
|
|
|
 //Antares Pharma (Ewing, NJ) has made its second major appointment in a month. Dr David Bergstrom joined the company as Senior VP of Pharmaceutical Development.//Voltarra Pharmaceuticals, Inc. (Bethlehem, PA) named Richard Becker as its new CEO.//StemCells, Inc. (Newark, CA) announced that Greg Schiffman will join its executive team as Chief Financial Officer and Executive Vice President of Finance, effective January 1, 2014.//Camargo Pharmaceutical Services (Cincinnati, OH) named Jim Beach as Chief Operating Officer.//The International Society for Pharmaceutical Engineering (ISPE; Tampa, FL) appointed Dr Thomas Zimmer to the newly created position of Vice President of European Operations.// |
|
|
|
|
|
 |
|
|
| |
|
|
 |
|
 |
Which area of pharma has the global recession impacted the most?
|
|
|
|
